Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ · Healthcare
Regeneron Pharmaceuticals, Inc. EBITDA 2008–2025
Regeneron Pharmaceuticals, Inc. annual/quarterly ebitda history and growth rate from 2008 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Regeneron Pharmaceuticals, Inc. ebitda for the quarter ending March 31, 2026 was 766.1 M, a 6.61% increase year-over-year.
- Regeneron Pharmaceuticals, Inc. ebitda for the twelve months ending March 31, 2026 was 3.4 B, a 10.62% decrease year-over-year.
- Regeneron Pharmaceuticals, Inc. annual ebitda for 2025 was 4.1 B, a 7.87% decrease from 2024.
- Regeneron Pharmaceuticals, Inc. annual ebitda for 2024 was 4.5 B, a 0.12% increase from 2023.
- Regeneron Pharmaceuticals, Inc. annual ebitda for 2023 was 4.5 B, a 12.05% decrease from 2022.
- Regeneron Pharmaceuticals, Inc. annual ebitda for 2022 was 5.1 B.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Regeneron Pharmaceuticals Inc. EBITDA — FAQ
Regeneron Pharmaceuticals Inc. (REGN) ebitda over the last 18 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see REGN's ebitda history?
The chart and table above show Regeneron Pharmaceuticals Inc.'s ebitda by year and by quarter, including the growth rate.